(Q68290032)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1670746%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

title

Doxazosin for the treatment of chronic congestive heart failure: results of a randomized double-blind and placebo-controlled study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1670746%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

Doxazosin for the treatment of chronic congestive heart failure: Results of a randomized double-blind and placebo-controlled study (English)

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

25 October 2022

1 reference

1 reference

congestive heart failure

1 reference

based on heuristic

inferred from title

Cardiology and cardiovascular medicine

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

25 October 2022

7

A Marlon

0 references

author name string

R. DiBianco

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1670746

25 October 2022

J. O. Parker

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1670746

25 October 2022

S. Chakko

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1670746

25 October 2022

P. H. Tanser

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1670746

25 October 2022

G. Emmanuel

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1670746

25 October 2022

J. B. Singh

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1670746

25 October 2022

A. Marlon

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1670746

25 October 2022

language of work or name

English

0 references

publication date

1 January 1991

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1670746%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

23 September 2019

https://api.elsevier.com/content/article/PII:000287039190875I?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

https://api.elsevier.com/content/article/PII:000287039190875I?httpAccept=text/plain

25 October 2022

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

25 October 2022

published in

American Heart Journal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1670746%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

volume

121

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1670746%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

issue

1 Pt 2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1670746%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

page(s)

372-380

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1670746%20AND%20SRC:MED&resulttype=core&format=json

Vasodilator therapy of cardiac failure: (first of two parts)

23 September 2019

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

Within patient comparison of prazosin and UK-33,274. A new alpha-adrenoceptor-antagonist

25 October 2022

3

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

Mechanism of alpha blockade for blood pressure control

25 October 2022

4

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

Clinical pharmacological studies with doxazosin

25 October 2022

5

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

Pharmacokinetic overview of doxazosin

25 October 2022

6

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

The antihypertensive effects of doxazosin: a clinical overview

25 October 2022

8

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

Efficacy and safety of doxazosin in hypertension therapy

25 October 2022

9

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

Clinical pharmacology of doxazosin in patients with essential hypertension.

25 October 2022

10

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

Doxazosin increases low density lipoprotein receptor activity.

25 October 2022

11

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

Double-blind comparison of the effects of long-term treatment with doxazosin or atenolol on serum lipoproteins

25 October 2022

12

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

Validation of a simple mechanical accelerometer (pedometer) for the estimation of walking activity.

25 October 2022

16

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

Measuring health status in arthritis. The arthritis impact measurement scales.

25 October 2022

18

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

The arthritis impact measurement scales. Further investigations of a health status measure

25 October 2022

19

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

Rationale for alpha-blockade in congestive heart failure

25 October 2022

21

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

Sustained reduction of cardiac impedance and preload in congestive heart failure with the antihypertensive vasodilator prazosin

25 October 2022

22

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

Long-term therapy of heart failure with prazosin: a randomized double blind trial

25 October 2022

23

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

Prazosin and congestive heart failure: short- and long-term therapy

25 October 2022

24

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

Long-Term Vasodilator Therapy with Trimazosin in Chronic Cardiac Failure

25 October 2022

25

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

Trimazosin in chronic congestive heart failure: Improved left ventricular function at rest and during exercise

25 October 2022

26

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

Acute hemodynamic and hormonal response to indoramin in congestive heart failure.

25 October 2022

27

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

Long-term indoramin therapy in congestive heart failure: a double-blind, randomized, parallel placebo-controlled trial.

25 October 2022

29

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

The hemodynamic and clinical responses to terazosin, a new alpha blocking agent, in congestive heart failure

25 October 2022

30

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

Differences in hemodynamic effects of nitroprusside and prazosin in severe chronic congestive heart failure: evidence for a direct negative chronotropic effect of prazosin

25 October 2022

31

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

Attenuation of Prazosin Effect on Cardiac Output in Chronic Heart Failure

25 October 2022

32

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

Vasodilatation with captopril and prazosin in chronic heart failure: double blind study at rest and on exercise

25 October 2022

34

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

Efficacy of prazosin in the management of chronic congestive heart failure: A 6-month randomized, double-blind, placebo-controlled study

25 October 2022

35

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

Marked early attenuation of hemodynamic effects of oral prazosin therapy in chronic congestive heart failure

25 October 2022

36

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure

25 October 2022

37

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

The renal response to neuroendocrine inhibition in chronic heart failure: double-blind comparison of captopril and prazosin.

25 October 2022

38

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

Therapeutic application of prazosin in chronic refractory congestive heart failure. Tolerance and "tachyphylaxis" in perspective

25 October 2022

39

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

Doxazosin, an alpha 1-adrenoceptor antagonist: pharmacokinetics and concentration-effect relationships in man

25 October 2022

42

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

Clinical assessment and follow-up of functional capacity in patients with chronic congestive cardiomyopathy

25 October 2022

44

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

Treadmill exercise in assessment of the functional capacity of patients with cardiac disease

25 October 2022

45

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study

25 October 2022

47

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

Alpha adrenergic contributions to dysrhythmia during myocardial ischemia and reperfusion in cats

25 October 2022

48

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

Cardioprotective and antidysrhythmic effects of alpha 1-adrenoceptor blockade during myocardial ischaemia and reperfusion in the dog

25 October 2022

49

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

Relative efficacy of vasodilator therapy in chronic congestive heart failure. Implications of randomized trials.

25 October 2022

50

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90875-I

25 October 2022

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1670746%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

1 reference